Lenvatinib Outperforms Placebo for Thyroid Ca

February 12, 2015 7:08 PM

3 0

Lenvatinib Outperforms Placebo for Thyroid Ca

Lenvatinib was associated with improved progression-free survival but also more serious adverse effects, compared with placebo when treating radioiodine-refractory thyroid cancer in a phase III randomized trial.

Median progression-free survival was 18.3 months for patients in the lenvatinib group versus 3.6 months for the placebo group (hazard ratio for progression or death 0.21, 99% CI 0.14-0.31, P<0.001), according to Martin Schlumberger, MD, at the Institute Gustave Roussy in France, and colleagues.

Read more

To category page

Loading...